In a post-hoc analysis, cariprazine seemed to be effective in treating both depressive and manic episodes of bipolar I disorder across age groups.

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

A recent study published in the Journal of Psychopharmacology has offered encouraging preliminary findings for individuals with severe obsessive-compulsive disorder who have not responded to standard ...

For those who suspect they might have sleep apnoea, it could be useful to try the Epworth Sleepiness Scale questionnaire. The ...

These days, it’s rare to hear conversations around climate change that have hope at the core, but for award-winning speaker ...

A new study, led by USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), will explore structural alterations in the brains of people with bipolar disorder (BD), a chronic ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

"By analyzing the largest-ever worldwide data collection, Dr. Ching is discovering the brain circuitry involved in bipolar disorder and how commonly prescribed medications influence the brain.

According to research published in Nature on January 22nd, 2025, an international team of psychiatric genetics researchers has discovered 298 regions of the genome with DNA variations that increase ...

Per the data readout from the phase IIb TRD study, 40 patients treated with GH001 achieved a significant 15.2-point reduction ...